Citigroup Downgrades Levi Strauss to Neutral, Lowers Price Target to $17
Citigroup analyst Paul Lejuez downgrades Levi Strauss (NYSE:LEVI) from Buy to Neutral and lowers the price target from $19 to $17.
JP Morgan Downgrades XPeng to Neutral, Lowers Price Target to $9
JP Morgan analyst Nick Lai downgrades XPeng (NYSE:XPEV) from Overweight to Neutral and lowers the price target from $11 to $9.
National Bank Of Canada Downgrades Stella-Jones to Sector Perform, Raises Price Target to C$54
National Bank Of Canada analyst Maxim Sytchev downgrades Stella-Jones (TSX:SJ) from Outperform to Sector Perform and raises the price target from C$53 to C$54.
Deutsche Bank Downgrades SiteOne Landscape Supply to Hold, Lowers Price Target to $126
Deutsche Bank analyst Joe Ahlersmeyer downgrades SiteOne Landscape Supply (NYSE:SITE) from Buy to Hold and lowers the price target from $144 to $126.
Goldman Sachs Downgrades STMicroelectronics to Sell
Goldman Sachs analyst Alexander Duval downgrades STMicroelectronics (NYSE:STM) from Neutral to Sell.
Goldman Sachs Downgrades Moelis & Co to Sell, Lowers Price Target to $37
Goldman Sachs analyst James Yaro downgrades Moelis & Co (NYSE:MC) from Neutral to Sell and lowers the price target from $40 to $37.
Cowen & Co. Downgrades Albireo Pharma to Market Perform, Lowers Price Target to $48
Cowen & Co. analyst Ritu Baral downgrades Albireo Pharma (NASDAQ:ALBO) from Outperform to Market Perform and lowers the price target from $68 to $48.
Credit Suisse Downgrades Motorola Solns to Neutral, Lowers Price Target to $270
Credit Suisse analyst Sami Badri downgrades Motorola Solns (NYSE:MSI) from Outperform to Neutral and lowers the price target from $300 to $270.
Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
Maxim Group Downgrades Amryt Pharma to Hold
Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.